Subject: Outcome of the Meeting of the Board of Directors of the Company
Dear Sir/ Madam,
In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform you that the Board of Directors at their meeting held today i.e., Wednesday, 30th March, 2022 (commenced at 06:00 P.M. and concluded at 06:30 P.M.), inter-alia, approved the allotment of 2,80,00,000 (Two Crore Eighty Lakh) Equity Shares of Rs. 2 each/-, to the following entities belonging to the promoter group of the Company ('Allottees'), arising out of conversion of 2,80,00,000 (Two Crore Eighty Lakh) Fully Convertible Warrants ('Warrants') of Rs. 25/- each (Rupees Twenty-Five only) (on receipt of Rs. 18.75/- per Warrant - being 75% of the balance Warrant issue price), which were issued pursuant to the shareholders' approval dated November 05, 2020 and allotted in the Board Meeting dated March 25, 2021, in accordance with the provisions of SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018:
Pursuant to the aforesaid allotment, the total number of Equity Shares has been increased from 44,98,26,203 to 47,78,26,203 Equity Shares. Further, the Equity Shares allotted as aforesaid, shall be kept under lock-in as per the provisions of SEBI (Issue of Capital and Disclosure
Requirements) Regulations 2018 and shall rank pari-passu with the existing Equity Shares, bearing ISIN - INE083A01026, of the Company in all respects, including with respect to dividend and voting powers.
In addition, we would like to apprise that the requisite details as required under SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 with respect to the aforesaid issue had already submitted to the Stock Exchanges on October 10, 2020.
You are requested to kindly take the same on your records.
Morepen Laboratories Ltd. published this content on 30 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 March 2022 14:12:07 UTC.
Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Febuxostat, Montelukast (Oral), Montelukast (Chewable), among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen 49W Room Air Purifier with HEPA Filter, Dr. Morepen VP06 Breathe Free Vaporizer, Dr. Morepen CN06 Compressor Nebulizer and Dr. Morepen ST03 Dual Head Stethoscope, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
MOREPEN LABORATORIES LIMITED 
